Zymeworks Inc (NASDAQ:ZYME) has received a consensus recommendation of “Hold” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $16.00.

ZYME has been the topic of several research analyst reports. Barclays PLC initiated coverage on shares of Zymeworks in a research note on Tuesday, May 23rd. They set an “overweight” rating and a $20.00 price target on the stock. Canaccord Genuity initiated coverage on shares of Zymeworks in a research note on Tuesday, May 23rd. They set a “buy” rating and a $18.00 price target on the stock. Wells Fargo & Company initiated coverage on shares of Zymeworks in a research note on Tuesday, May 23rd. They set an “outperform” rating and a $20.00 price target on the stock. Citigroup Inc. initiated coverage on shares of Zymeworks in a research note on Tuesday, May 23rd. They set a “buy” rating and a $18.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Zymeworks from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th.

A number of hedge funds and other institutional investors have recently bought and sold shares of ZYME. OxFORD Asset Management LLP acquired a new position in Zymeworks in the second quarter valued at $154,000. Sentry Investments Corp. acquired a new position in Zymeworks in the second quarter valued at $206,000. Barometer Capital Management Inc. acquired a new position in Zymeworks in the second quarter valued at $484,000. Finally, Franklin Resources Inc. acquired a new position in Zymeworks in the second quarter valued at $6,878,000.

TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/07/zymeworks-inc-zyme-receives-average-rating-of-hold-from-analysts.html.

Shares of Zymeworks (ZYME) traded down 6.89% during midday trading on Thursday, hitting $7.70. 29,565 shares of the stock were exchanged. The stock has a 50 day moving average price of $7.47 and a 200-day moving average price of $9.28. Zymeworks has a 12 month low of $6.25 and a 12 month high of $14.25. The company’s market cap is $195.11 million.

About Zymeworks

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Analyst Recommendations for Zymeworks (NASDAQ:ZYME)

Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with MarketBeat.com's FREE daily email newsletter.